However, a progressive decrease in MDSCs was observed during ibrutinib therapy, potentially due to a direct effect on BTK in MDSCs or an indirect effect mediated by reduced signaling from CLL cells that typically occurs following BCR activation [72]. This evidence concerns the gene BCR and B-cell chronic lymphocytic leukemia.